select a format

Single User License
USD 2000 INR 0
Site License
USD 4000 INR 0
Corporate User License
USD 6000 INR 0

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Liver Cirrhosis-Pipeline Review, H2 2016

Liver Cirrhosis-Pipeline Review, H2 2016


  • Products Id :- GMDHC8434IDB
  • |
  • Pages: 86
  • |
  • August 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Liver Cirrhosis-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Liver Cirrhosis-Pipeline Review, H2 2016', provides an overview of the Liver Cirrhosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis

The report reviews pipeline therapeutics for Liver Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Liver Cirrhosis therapeutics and enlists all their major and minor projects

The report assesses Liver Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Liver Cirrhosis

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Liver Cirrhosis Overview 8

Therapeutics Development 9

Pipeline Products for Liver Cirrhosis-Overview 9

Pipeline Products for Liver Cirrhosis-Comparative Analysis 10

Liver Cirrhosis-Therapeutics under Development by Companies 11

Liver Cirrhosis-Therapeutics under Investigation by Universities/Institutes 12

Liver Cirrhosis-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Liver Cirrhosis-Products under Development by Companies 16

Liver Cirrhosis-Products under Investigation by Universities/Institutes 17

Liver Cirrhosis-Companies Involved in Therapeutics Development 18

Conatus Pharmaceuticals Inc. 18

Digna Biotech, S.L. 19

Galectin Therapeutics, Inc. 20

Human Stem Cells Institute 21

Nimbus Therapeutics, LLC 22

Ocera Therapeutics, Inc. 23

Pharmicell Co., Ltd. 24

S-Evans Biosciences, Inc. 25

Stelic Institute & Co., Inc. 26

Liver Cirrhosis-Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

Cellgram-LC-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

DB-027-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

DB-036-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

emricasan-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Gemacell-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

GRMD-02-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

GXHPC-1-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

ND-654-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

ornithine phenylacetate-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis and Pneumoconiosis-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Stem Cell Therapy for Liver Cirrhosis and Rheumatoid Arthritis-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

STNM-04-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Liver Cirrhosis-Dormant Projects 71

Liver Cirrhosis-Discontinued Products 72

Liver Cirrhosis-Product Development Milestones 73

Featured News & Press Releases 73

May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial 73

Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data 74

Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting 75

Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial 76

Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting 77

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 78

Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting 78

Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting 79

Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement 79

May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam 81

Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 82

Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 83

Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 83

Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis 84

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86

List of Figures

Number of Products under Development for Liver Cirrhosis, H2 2016 9

Number of Products under Development for Liver Cirrhosis-Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Top 10 Targets, H2 2016 28

Number of Products by Stage and Top 10 Targets, H2 2016 28

Number of Products by Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

List of Tables

Number of Products under Development for Liver Cirrhosis, H2 2016 9

Number of Products under Development for Liver Cirrhosis-Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Liver Cirrhosis-Pipeline by Conatus Pharmaceuticals Inc., H2 2016 18

Liver Cirrhosis-Pipeline by Digna Biotech, S.L., H2 2016 19

Liver Cirrhosis-Pipeline by Galectin Therapeutics, Inc., H2 2016 20

Liver Cirrhosis-Pipeline by Human Stem Cells Institute, H2 2016 21

Liver Cirrhosis-Pipeline by Nimbus Therapeutics, LLC, H2 2016 22

Liver Cirrhosis-Pipeline by Ocera Therapeutics, Inc., H2 2016 23

Liver Cirrhosis-Pipeline by Pharmicell Co., Ltd., H2 2016 24

Liver Cirrhosis-Pipeline by S-Evans Biosciences, Inc., H2 2016 25

Liver Cirrhosis-Pipeline by Stelic Institute & Co., Inc., H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Liver Cirrhosis-Dormant Projects, H2 2016 71

Liver Cirrhosis-Discontinued Products, H2 2016 72

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Conatus Pharmaceuticals Inc.

Digna Biotech, S.L.

Galectin Therapeutics, Inc.

Human Stem Cells Institute

Nimbus Therapeutics, LLC

Ocera Therapeutics, Inc.

Pharmicell Co., Ltd.

S-Evans Biosciences, Inc.

Stelic Institute & Co., Inc.

Liver Cirrhosis Therapeutic Products under Development, Key Players in Liver Cirrhosis Therapeutics, Liver Cirrhosis Pipeline Overview, Liver Cirrhosis Pipeline, Liver Cirrhosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com